News: NOX Noxopharm Says Veyonda Survival Advantage In LuPSMA Therapy Confirmed

  1. 193,698 Posts.
    lightbulb Created with Sketch. 2825

    Aug 5 (Reuters) - Noxopharm Ltd (NOX) :

    • VEYONDA SURVIVAL ADVANTAGE IN LUPSMA THERAPY CONFIRMED
    • ANIMAL STUDY SHOWS ADDING VEYONDA TO 177LUTETIUM-PSMA-617 RESULTS IN REGRESSION OF PROSTATE CANCER
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
9.8¢
Change
0.000(0.00%)
Mkt cap ! $28.63M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
2 73788 9.7¢
 

Sellers (Offers)

Price($) Vol. No.
10.0¢ 100747 1
View Market Depth
Last trade - 10.40am 12/09/2025 (20 minute delay) ?
NOX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.